Researchers are redesigning peptides so they can be swallowed and still reach specific targets, a step toward a new class of precision pills.
Recap by typeshit. Full story at The News & Observer on MSN.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Experts quoted in the piece suggest the spread of GLP-1 drugs could shape how non-users feel about their own bodies and health.
The FDA put both companies on an import alert, which lets it stop their products at the US border, News Nation reports.
Loading…